Jones Trading Begins Coverage on Palvella Therapeutics (NASDAQ:PVLA)

Jones Trading initiated coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note published on Tuesday morning,Benzinga reports. The brokerage issued a buy rating and a $45.00 target price on the stock.

PVLA has been the topic of several other reports. TD Cowen initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday, February 5th. They set a “buy” rating and a $44.00 target price on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $39.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Cantor Fitzgerald began coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating for the company. HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, February 11th. Finally, Scotiabank began coverage on shares of Palvella Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $43.20.

Palvella Therapeutics Price Performance

PVLA stock opened at $27.27 on Tuesday. The business has a 50 day simple moving average of $19.36. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $29.27. The company has a market capitalization of $306.00 million, a P/E ratio of -2.25 and a beta of 0.54.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Suvretta Capital Management LLC acquired a new stake in shares of Palvella Therapeutics in the fourth quarter worth $8,574,000. BVF Inc. IL acquired a new stake in Palvella Therapeutics in the 4th quarter worth $8,359,000. Samsara BioCapital LLC acquired a new stake in Palvella Therapeutics in the 4th quarter worth $8,154,000. Frazier Life Sciences Management L.P. bought a new position in shares of Palvella Therapeutics during the 4th quarter worth about $7,847,000. Finally, Adams Street Partners LLC acquired a new position in shares of Palvella Therapeutics during the fourth quarter valued at about $4,916,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.